Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.
Adult
Aged
Antineoplastic Agents, Alkylating
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ pharmacokinetics
Area Under Curve
DNA Repair
/ drug effects
Dose-Response Relationship, Drug
Drug Synergism
Female
Half-Life
Humans
Hydroxylamines
/ administration & dosage
Male
Maximum Tolerated Dose
Metabolic Clearance Rate
Middle Aged
Neoplasms
/ drug therapy
Temozolomide
/ adverse effects
DNA repair
Methoxyamine
Phase I
TRC-102
Temozolomide
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
17
05
2020
accepted:
11
06
2020
pubmed:
20
6
2020
medline:
1
2
2022
entrez:
20
6
2020
Statut:
ppublish
Résumé
Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N
Identifiants
pubmed: 32556884
doi: 10.1007/s10637-020-00962-x
pii: 10.1007/s10637-020-00962-x
pmc: PMC7744386
mid: NIHMS1605069
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Hydroxylamines
0
methoxyamine
9TZH4WY30J
Temozolomide
YF1K15M17Y
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-151Subventions
Organisme : NCI NIH HHS
ID : R01 CA086357
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA126149
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA076917
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA043703
Pays : United States
Références
PLoS One. 2015 Aug 26;10(8):e0131330
pubmed: 26309022
Nucl Med Biol. 2009 Nov;36(8):975-83
pubmed: 19875055
Nat Rev Cancer. 2012 Dec;12(12):801-17
pubmed: 23175119
J Clin Oncol. 2006 Jan 20;24(3):401-6
pubmed: 16421420
Mutat Res. 2001 May 10;485(4):269-81
pubmed: 11585361
Clin Cancer Res. 2007 Mar 1;13(5):1532-9
pubmed: 17332299
Cell Death Dis. 2012 Jan 12;3:e252
pubmed: 22237209
Exp Cell Res. 1988 Mar;175(1):184-91
pubmed: 3345800
Leukemia. 2010 Oct;24(10):1795-9
pubmed: 20811400
Environ Mol Mutagen. 2000;35(3):206-21
pubmed: 10737956
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:25-33
pubmed: 22743337
Clin Cancer Res. 2002 Sep;8(9):2985-91
pubmed: 12231545
Cancer. 2011 Jan 15;117(2):268-75
pubmed: 20824724
Invest New Drugs. 2013 Jun;31(3):714-23
pubmed: 23054206
J Clin Oncol. 2012 Aug 20;30(24):2963-8
pubmed: 22778320
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437